Veopoz® (Pozelimab-Bbfg) – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers Veopoz (pozelimab‑bbfg) only for CD55‑deficient protein‑losing enteropathy (CHAPLE disease) and excludes other indications and concurrent use with C5 inhibitors (e.g., eculizumab, ravulizumab). Coverage requires documentation of a biallelic CD55 loss‑of‑function mutation and clinical/lab evidence of CHAPLE, dosing per FDA labeling, prescription by a hematologist or qualified specialist, initial and reauthorizations limited to ≤12 months, and continuation only with documented clinical improvement (FDA age ≥1 year; meningococcal vaccination/prophylaxis per labeling noted).

"Dosing information consistent with FDA-approved labeling (to be documented with the request)."

Sign up to see full coverage criteria, indications, and limitations.